Osseon Therapeutics, a Santa Rosa, CA-based company that develops and commercialize medical devices for minimally invasive treatments for degenerative bone and joint disease, including the treatment of vertebral compression fractures, raised $14m in equity financing.
The round was led by an unnamed private investor.
The company intends to use the capital to expand its VCF device product line.
Led by CEO Ron Clough, Osseon Therapeutics designs, manufactures and distributes patented, steerable delivery systems that are designed to improve the quality of life for patients with vertebral compression fractures (VCF) which may result from osteoporosis, osteotraumatic injuries, myelomas or other degenerative bone diseases. The company’s products are distributed globally.
FinSMEs
31/01/2013